These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 24949569)

  • 1. Effect of environmental cues on the behavioral efficacy of haloperidol, olanzapine, and clozapine in rats.
    Sun T; Liu X; Li M
    Behav Pharmacol; 2014 Aug; 25(4):277-86. PubMed ID: 24949569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time-dependent sensitization of antipsychotic effect in adolescent male and female rats.
    Ding X; Li X; Shu Q; Wu R; Hu G; Li M
    Behav Brain Res; 2017 Jun; 328():186-194. PubMed ID: 28412306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated asenapine treatment produces a sensitization effect in two preclinical tests of antipsychotic activity.
    Qin R; Chen Y; Li M
    Neuropharmacology; 2013 Dec; 75():356-64. PubMed ID: 23954676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adult response to olanzapine or clozapine treatment is altered by adolescent antipsychotic exposure: a preclinical test in the phencyclidine hyperlocomotion model.
    Shu Q; Hu G; Li M
    J Psychopharmacol; 2014 Apr; 28(4):363-75. PubMed ID: 24257809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contextual and behavioral control of antipsychotic sensitization induced by haloperidol and olanzapine.
    Zhang C; Li M
    Behav Pharmacol; 2012 Feb; 23(1):66-79. PubMed ID: 22157143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated antipsychotic treatment progressively potentiates inhibition on phencyclidine-induced hyperlocomotion, but attenuates inhibition on amphetamine-induced hyperlocomotion: relevance to animal models of antipsychotic drugs.
    Sun T; Hu G; Li M
    Eur J Pharmacol; 2009 Jan; 602(2-3):334-42. PubMed ID: 19059234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neural basis of the potentiated inhibition of repeated haloperidol and clozapine treatment on the phencyclidine-induced hyperlocomotion.
    Zhao C; Sun T; Li M
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Aug; 38(2):175-82. PubMed ID: 22476004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated effects of the neurotensin receptor agonist PD149163 in three animal tests of antipsychotic activity: assessing for tolerance and cross-tolerance to clozapine.
    Chou S; Davis C; Jones S; Li M
    Pharmacol Biochem Behav; 2015 Jan; 128():78-88. PubMed ID: 25433325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Environmental and behavioral controls of the expression of clozapine tolerance: evidence from a novel across-model transfer paradigm.
    Feng M; Sui N; Li M
    Behav Brain Res; 2013 Feb; 238():178-87. PubMed ID: 23092709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct neural mechanisms underlying acute and repeated administration of antipsychotic drugs in rat avoidance conditioning.
    Li M; Sun T; Zhang C; Hu G
    Psychopharmacology (Berl); 2010 Sep; 212(1):45-57. PubMed ID: 20623111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time course of the attenuation effect of repeated antipsychotic treatment on prepulse inhibition disruption induced by repeated phencyclidine treatment.
    Li M; He E; Volf N
    Pharmacol Biochem Behav; 2011 Jun; 98(4):559-69. PubMed ID: 21402097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats.
    Amitai N; Semenova S; Markou A
    Psychopharmacology (Berl); 2007 Sep; 193(4):521-37. PubMed ID: 17497138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice.
    Gleason SD; Shannon HE
    Psychopharmacology (Berl); 1997 Jan; 129(1):79-84. PubMed ID: 9122367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia.
    Sparkman NL; Li M
    Behav Pharmacol; 2012 Oct; 23(7):658-68. PubMed ID: 22903071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parametric studies of antipsychotic-induced sensitization in the conditioned avoidance response model: roles of number of drug exposure, drug dose, and test-retest interval.
    Swalve N; Li M
    Behav Pharmacol; 2012 Aug; 23(4):380-91. PubMed ID: 22732209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine.
    Bakshi VP; Geyer MA
    Psychopharmacology (Berl); 1995 Nov; 122(2):198-201. PubMed ID: 8848537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of atypical antipsychotics and phencyclidine (PCP) on rotorod performance.
    Steinpreis RE; Anders KA; Branda EM; Kruschel CK
    Pharmacol Biochem Behav; 1999 Jul; 63(3):387-94. PubMed ID: 10418778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term impacts of adolescent risperidone treatment on behavioral responsiveness to olanzapine and clozapine in adulthood.
    Qiao J; Zhang Q; Li M
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():177-85. PubMed ID: 24140929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different effects of a single and repeated administration of clozapine on phencyclidine-induced hyperlocomotion and glutamate releases in the rat medial prefrontal cortex at short- and long-term withdrawal from this antipsychotic.
    Abekawa T; Ito K; Koyama T
    Naunyn Schmiedebergs Arch Pharmacol; 2007 Jun; 375(4):261-71. PubMed ID: 17458542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine and clozapine but not haloperidol reverse subchronic phencyclidine-induced functional hyperactivity of N-methyl-D-aspartate receptors in pyramidal cells of the rat medial prefrontal cortex.
    Ninan I; Jardemark KE; Wang RY
    Neuropharmacology; 2003 Mar; 44(4):462-72. PubMed ID: 12646283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.